Sarepta Therapeutics Inc. (SRPT) Receives “Outperform” Rating from RBC Capital Markets
Sarepta Therapeutics Inc. (NASDAQ:SRPT)‘s stock had its “outperform” rating reaffirmed by analysts at RBC Capital Markets in a report released on Monday. They presently have a $108.00 target price on the stock. RBC Capital Markets’ price target indicates a potential upside of 106.58% from the stock’s current price.
A number of other equities research analysts have also recently issued reports on SRPT. Oppenheimer Holdings Inc. reissued a “buy” rating and issued a $60.00 target price on shares of Sarepta Therapeutics in a research report on Sunday, July 17th. Jefferies Group set a $58.00 target price on shares of Sarepta Therapeutics and gave the company a “hold” rating in a research report on Sunday, October 2nd. Robert W. Baird reissued an “outperform” rating and issued a $102.00 target price on shares of Sarepta Therapeutics in a research report on Monday. William Blair raised shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $88.00 target price for the company in a research report on Monday, September 19th. Finally, Piper Jaffray Cos. raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Monday, September 19th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $60.91.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded down 4.44% during midday trading on Monday, reaching $49.96. 2,848,133 shares of the company’s stock were exchanged. The company’s 50 day moving average is $45.03 and its 200-day moving average is $26.60. The stock’s market cap is $2.39 billion. Sarepta Therapeutics has a 12 month low of $8.00 and a 12 month high of $63.73.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/17/sarepta-therapeutics-inc-srpt-receives-outperform-rating-from-rbc-capital-markets.html
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same period in the previous year, the company earned ($0.87) EPS. Equities analysts forecast that Sarepta Therapeutics will post ($4.23) EPS for the current fiscal year.
In other Sarepta Therapeutics news, CEO Edward M. Md Kaye sold 24,557 shares of the stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $30.00, for a total transaction of $736,710.00. Following the transaction, the chief executive officer now directly owns 76,983 shares in the company, valued at approximately $2,309,490. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Edward M. Md Kaye sold 24,352 shares of the stock in a transaction that occurred on Monday, September 19th. The stock was sold at an average price of $50.00, for a total value of $1,217,600.00. Following the transaction, the chief executive officer now owns 89,983 shares in the company, valued at $4,499,150. The disclosure for this sale can be found here. 10.90% of the stock is owned by corporate insiders.
Institutional investors have recently bought and sold shares of the company. Teacher Retirement System of Texas boosted its position in Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock worth $115,000 after buying an additional 724 shares during the last quarter. Advisor Group Inc. acquired a new position in Sarepta Therapeutics during the second quarter worth about $154,000. Quantitative Systematic Strategies LLC acquired a new position in Sarepta Therapeutics during the second quarter worth about $211,000. BNP Paribas Arbitrage SA boosted its position in Sarepta Therapeutics by 114.0% in the third quarter. BNP Paribas Arbitrage SA now owns 3,541 shares of the company’s stock worth $217,000 after buying an additional 1,886 shares during the last quarter. Finally, National Planning Corp boosted its position in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares during the last quarter. Hedge funds and other institutional investors own 65.06% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.